NCT07117890

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

a Study of Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	sunvozertinib 300mg	sunvozertinib monotherapy, 300mg QD
DRUG	sunvozertinib 200mg	sunvozertinib monotherapy, 200mg QD

Timeline

• Start date: 2025-02-07
• Primary completion: 2027-02-20
• Completion: 2027-05-30
• First posted: 2025-08-12
• Last updated: 2025-12-24

Locations

1 site across 1 country: China